Skip to main content
. 2023 Jan 28;20(1):23–31. doi: 10.26599/1671-5411.2023.01.007

Table 1. Patient characteristics.

Characteristics All n = 704 < 1 yr n = 76 > 1 yr n = 173
Data are presented as n (%) unless other indicated. COPD: chronic obstructive pulmonary disease; CRT-D: cardiac resynchronization therapy defibrillators; CVA: cerebrovascular accident; TIA: Transient ischemic attack.
Age in years (range) 82.0 (81.0-83.0) 82.0 (81.0-84.0) 81.0 (80.0-83.0)
Male 585 (83.1%) 67 (88.2%) 144 (83.2%)
EF in % (range) 33.0 (26.0-45.0) 30.0 (25.0-40.0) 33.0 (27.0-45.0)
NYHA class
 I 54 (7.7%) 6 (7.9%) 11 (6.4%)
 II 476 (67.6%) 50 (65.8%) 114 (65.9%)
 III-IV 174 (24.7%) 20 (26.3%) 48 (27.8%)
Comorbidities
 Diabetes 83 (11.8%) 10 (13.2%) 20 (11.6%)
 COPD 51 (7.2%) 8 (10.5%) 11 (6.4%)
 CVA/TIA 40 (5.7%) 3 (3.9%) 10 (5.8%)
 Oncologic 34 (4.8%) 7 (9.2%) 10 (5.8%)
 Renal failure 116 (16.5%) 14 (18.4%) 24 (13.9%)
 Atrial fibrillation 244 (34.7%) 30 (39.5%) 59 (34.1%)
LBBB 183 (26.0%) 18 (24.7%) 30 (17.3%)
Upgrade from pacemaker 80 (11.4%) 11 (14.5%) 13 (7.5%)
Prevention
 Primary 385 (54.7%) 30 (39.5%) 83 (48.0%)
 Secondary 319 (45.3%) 46 (60.5%) 90 (52.0%)
Indication
 Ischemic 471 (66.9%) 51 (67.1%) 125 (72.3%)
 Non-ischemic 233 (33.1%) 25 (32.9%) 48 (27.7%)
Type of device
 VVI/DDD 541 (76.8%) 63 (82.9%) 135 (78.0%)
 CRT-D 163 (23.2%) 13 (17.1%) 38 (22.0%)
QRS duration
 < 120 ms 458 (65.0%) 49 (64.5%) 123 (71.1%)
 120-150 ms 67 (10.0%) 11 (14.5%) 5 (2.9%)
 > 150 ms 179 (25.0%) 16 (21.0%) 45 (26.0%)